AVT03

BIOLOGICAL3 trials

Sponsors

Alvotech Swiss AG

Conditions

Healthy Male SubjectsOsteoporosis, PostmenopausalThis is a Phase I Study Conducted in Healthy Volunteers

Phase 1

AVT03 With Prolia in Healthy Male Subjects

CompletedNCT05126784

Alvotech Swiss AGHealthy Male Subjects

Start: 2022-06-29End: 2023-10-16Updated: 2024-05-29

AVT03 With Xgeva in Healthy Male Subjects

CompletedNCT05876949

Alvotech Swiss AGThis is a Phase I Study Conducted in Healthy Volunteers

Start: 2023-07-21End: 2024-04-15Updated: 2025-05-15

Phase 3

Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND

CompletedNCT05395091

Alvotech Swiss AGOsteoporosis, Postmenopausal

Start: 2022-08-23End: 2024-10-28Updated: 2025-05-29

Related Papers

A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosis

Expert Opinion on Biological Therapy2025-07-231 citations

A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (60 mg/mL) in healthy male adults

Expert Opinion on Investigational Drugs2025-05-131 citations

A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL) in healthy male adults

Expert Opinion on Investigational Drugs2025-05-13